|

ATX-295 Clinical Trials

1 actively recruiting trial across 1 location

No change since August 2026

Pipeline

Phase 1: 1

Top Sponsors

  • Accent Therapeutics1

Indications

  • High-grade Serous Ovarian Carcinoma1
  • Breast Cancer Recurrent1
  • Triple Negative Breast Cancer1
  • Advanced Solid Tumors1
  • Ovarian Cancer1

Aurora, Colorado1 trial

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

University of Colorado Denver

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.